Talk One: Impact of Presenting Stage on Overall Survival in Patients Treated with Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
Jenn F. Carroll, MD

Talk Two: Omission of ALND in the Setting of Mastectomy and 1-2 Positive SLN's
Shon M. Black, MD


LEARNING OBJECTIVES
Upon conclusion of this activity, participants should be able to:

Talk One:

• Identify the expected adjuvant treatment for patients with residual disease following neoadjuvant chemotherapy for triple negative breast cancer
• Cite the impact of the extent of disease at presentation on the expected overall survival of patients with triple negative breast cancer following neoadjuvant chemotherapy

Talk Two:

• Define the indications for omitting axillary node dissection in the setting mastectomy and 1-2 positive sentinel nodes
• Summarize the outcome of the randomized trials comparing axillary dissection versus no axillary dissection in the setting of mastectomy and 1-2 positive sentinel nodes
• Demonstrate axillary management practice pattern changes in patients undergoing mastectomy with 1-2 positive sentinel node

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows. Attendance must be manually recorded in MedHub. Contact MSCGME support staff for assistance.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.